Christopher Moxham
Chief Executive Officer presso Rarebase, PBC
Profilo
Dr. Christopher Moxham is a Chief Executive & Scientific Officer at Transcripta Bio, Inc. and a President & Chief Executive Officer at Rarebase, PBC.
Dr. Moxham was previously employed as a Chief Scientific Officer by Fulcrum Therapeutics, Inc. and a Head-Drug Discovery by Eli Lilly & Co.
He received his undergraduate degree from Cornell University and a doctorate degree from Stony Brook University.
Posizioni attive di Christopher Moxham
| Società | Posizione | Inizio |
|---|---|---|
Rarebase, PBC
 Rarebase, PBC Packaged SoftwareTechnology Services Rarebase, PBC is a biotech company that is dedicated to discovering and developing medicines for rare diseases. The company is based in Palo Alto, CA and was founded by Onno Faber and Omid Karkouti. The company has a product engine that is designed to discover treatments for hundreds of monogenic diseases simultaneously. Rarebase has already uncovered potential treatments for hundreds of rare diseases and has built a "drug-gene atlas" to enable AI-driven drug discovery. Onno Faber has been the CEO since incorporation. | Chief Executive Officer | 04/10/2023 |
Precedenti posizioni note di Christopher Moxham
| Società | Posizione | Fine |
|---|---|---|
| ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
| FULCRUM THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Formazione di Christopher Moxham
| Stony Brook University | Doctorate Degree |
| Cornell University | Undergraduate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| ELI LILLY AND COMPANY | Health Technology |
| FULCRUM THERAPEUTICS, INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Rarebase, PBC
Rarebase, PBC Packaged SoftwareTechnology Services Rarebase, PBC is a biotech company that is dedicated to discovering and developing medicines for rare diseases. The company is based in Palo Alto, CA and was founded by Onno Faber and Omid Karkouti. The company has a product engine that is designed to discover treatments for hundreds of monogenic diseases simultaneously. Rarebase has already uncovered potential treatments for hundreds of rare diseases and has built a "drug-gene atlas" to enable AI-driven drug discovery. Onno Faber has been the CEO since incorporation. | Technology Services |
- Borsa valori
- Insiders
- Christopher Moxham
